TABLE 2.
Results of primary and composite outcome according to the study group (FAS population).
| Variable | Losartan group (n=284) | BYF group (n=283) | Difference (95% CI) | P |
|---|---|---|---|---|
| Primary outcome | ||||
| Unadjusted eGFR slope (SE) a | −4.53 (0.64) | −2.30 (0.63) | −2.24 (−4.01, −0.46) | 0.014 |
| Secondary outcomes | ||||
| Composite endpoint# | 95 (36.4%) | 73 (28.1%) | 0.61 (0.44, 0.85) b | 0.003 |
| ESKD# | 91 (34.9%) | 71 (27.3%) | 0.61 (0.43, 0.85) b | 0.004 |
| Stroke or cardiovascular events | 3 (1.1%) | 1 (0.4%) | - | |
| Death | 0 | 1 (0.4%) | - | |
| Doubling of serum creatinine | 1 (0.4%) | 0 | - | |
a
eGFR slope calculated in the mixed-effects model, no adjustment.# 18 cases without available data and 28 ineligible cases (ESKD at baseline) were excluded from analysis (23 in the losartan group and 23 in the BYF group).
b
Shown as Cox regression analysis results, HR (95%CI), adjusted center effect, sex, age, weight, systolic pressure, hypertension history and gout/hyperuricemia history.
BYF, Bupi Yishen Formula; CI, confidence interval; SE, standard error; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease.